Melanin concentrating hormone receptor-1 antagonists
AssigneeBristol-Myers Squibb Company
InventorGuohua Zhao
Life of this patent
Estimating the term…
Abstract
The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R1a, R1b, R1c, Q, A, R3, W, D and R2 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.
Claims34
A compound or a pharmaceutically acceptable salt or a stereoisomer or a solvate or a prodrug of Formula I
- wherein
- A is selected from the group consisting of mono-cyclic aryl, mono-cyclic heteroaryl and bi-cyclic heteroaryl;
- D is selected from the group consisting of a direct bond, alkyl, cycloalkyl and heterocyclyl;
- Q is selected from the group consisting of —(CR1R9)n—, —C(R1R9)C(O)—, —C(O)C(R1R9)—, —(CO)m—, —C(O)CR8R9C(O)—, and —CR8=CR9—;
- W is selected from the group consisting of a direct bond, —C(O)—, —O—, —N(R9a)—, —S(O)—, —S(O2)—, —S(O2)N(R9a)— and —C(R10)(R11)—;
- R1a, R1b and R1c are independently selected from the group consisting of hydrogen, halo, aryl, aryloxy, arylthio, arylalkylthio, and heteroaryl, wherein aryl and heteroaryl, alone or as part of another group, may optionally and independently, be substituted with 1-3 R4;
- R2 is selected from the group consisting of hydrogen, hydroxyl, lower alkoxy, hydroxyalkyl, lower cycloalkoxy, OCONR7R7a, CN, CONR7R7a, SOR6, SO2R6, NR7COR7b, NR7CO2R7b, CO2R6, heterocyclyl, heteroaryl, NR7R7a, NR7 SO2R6 and COR6;
- R3 is selected from the group consisting of hydrogen, hydroxyl, alkoxy, halo, CN, alkyl, perfluoroalkyl, cycloalkyl and cycloalkoxy, wherein R3 and D may optionally be taken together with the atoms to which they are attached to form a 5 to 7-membered ring;
- R4 is selected from the group consisting of alkyl, halo, polyfluoroalkyl, alkoxy, polyfluoroalkyloxy, CN and alkylthio;
- R6 is independently selected from the group consisting of lower alkyl and lower cycloalkyl;
- and
- R7, R7a and R7b are independently selected from the group consisting of hydrogen, lower alkyl and lower cycloalkyl, wherein two R7 and the atom to which they are attached may optionally form a heterocyclyl of 4 to 7 atoms.
- R8, R9, and R9a, R10 and R11 are independently selected from the group consisting of hydrogen and alkyl;
- m is an integer from 1 to 2;
- n is an integer from 1 to 4;
- or
- a pharmaceutically acceptable salt or a stereoisomer or a solvate or a prodrug ester thereof.
Dependencies are inferred from the claim text.